HANCOCK DANIEL M 4

What Happened Daniel M. Hancock, a director of Cryoport, Inc. (CYRX), was granted a total of 26,427 equity awards on June 5, 2026. The filing shows two grant entries: 10,350 shares reported as an award (price $0.00) and 16,077 reported as a derivative award (price $0.00). No cash was paid for these grants (total reported value $0).

Key Details

• Transaction date: June 5, 2026; Form 4 filed June 8, 2026 (filed within the normal reporting window).
• Reported grants: 10,350 shares (award) and 16,077 derivative awards — total 26,427 units.
• Reported price: $0.00 (awards/grants; no purchase price).
• Shares owned after transaction: not specified in the information provided in the summary.
• Footnotes from the filing:
  • F1: The 16,077 derivative awards are restricted stock rights that vest in full on June 5, 2027 and, upon vesting, convert one-for-one into common shares.
  • F2: A separate vesting schedule noted in the filing indicates 1/12th of certain options vest monthly on the 5th of each month for 12 months beginning July 5, 2026.

Context

• These are award-based grants (code A) rather than open-market purchases or sales; awards at $0 are typical for restricted stock/right grants and do not represent an immediate cash outlay by the insider.
• Restricted stock rights and scheduled-option vesting mean the awards are subject to future vesting conditions; they do not immediately increase freely tradeable shares.
• Such grants are routine compensation or board-related awards and should be evaluated alongside company disclosures (proxy/compensation table) for context; they are factual reporting of insider holdings, not an explicit market sentiment signal.